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Abstract
Antibiotic resistance is closely related to antibiotic use and Italy is a country with high levels of both antibiotic use and antimicrobial
resistance. We analysed the trend in antibiotic use in the community among adults (‡15 years) and elderly, in the period 2003–2009, in
Emilia-Romagna, Italy, a region with over 4 000 000 inhabitants. Data regarding antibiotic use were obtained from the regional public
health system databases. Between 2003 and 2009 the antibiotic consumption increased from 15.4 to 18.7 deﬁned daily doses/1000
inhabitants per day (DID) (+21.4%, p <0.0001). The prescription rate in 2009 was 2.19 prescriptions/1000 inhabitants per day, an
increase of 13.8% compared with 2003. The highest increase in antibiotic use was observed among persons aged 20–59 years (+24.7%).
The proportion of inhabitants receiving at least one antibiotic treatment was 36.4% in 2003 and 39.7% in 2009, and the proportions
receiving at least three antibiotic treatments were 3.5% and 4.2%, respectively. The H1N1 pandemic was associated, in October and
November 2009, with a 37–90% increase in antibiotic use among the 15–19-year and 20–59-year age groups compared with 2007 and
2008. No other difference was observed in any other age group. The analysis per antibiotic class showed increases for penicillin + beta-
lactamase inhibitor (from 3.6 to 6.3 DID), quinolones (from 2.6 to 3.0 DID) and macrolides (from 3.1 to 3.7 DID), whereas cephalospo-
rin use was stable (1.4 DID). A steady increase in antibiotic use in the adult population has been observed in the Emilia-Romagna: public
health interventions are mandatory to counteract this trend.
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Introduction
Bacteria are probably the most adaptable organisms on earth
[1]. The use of antibiotics is closely related to the selection
of resistance, which is considered an emerging threat [2,3].
This problem, which has reached the lay public [4], is compli-
cated by the limited numbers of new antibiotic agents regis-
tered in the last decade and of those that are in the
industries’ pipelines for the next decade [5]. Antibiotic resis-
tance, a natural event that is estimated to be at least 2 billion
years old [6], will be a problem to face for many years to
come, possibly forever, unless strategies other than antibiotic
use become widely employed to ﬁght bacterial infections.
Antibiotic over-prescription, a common problem, is clo-
sely related to resistance [7–9], although antibiotic use alone
does not explain all the aspects of resistance induction [10].
The majority of antibiotics are prescribed in the community
to treat mild to medium severity infections, in Italy over 85%
[11]. Programmes to control antibiotic use have therefore to
be implemented in this setting, focusing both on the indica-
tions for treatment and antibiotic class selection [12]. Anti-
biotic use should aim for the most favourable outcome in
the individual patient as well as for the minimization of anti-
microbial resistance [13].
Italy is among the top antibiotic user in Europe with over
25 deﬁned daily doses per 1000 inhabitants per day (DID),
over twice that of the Netherlands [14]. Nonetheless even
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in these ‘low-antibiotic-use’ countries a proportion of the
antibiotic prescriptions is inadequate [15].
The aim of this study was to analyse the trends in anti-
biotic prescription in the community in Emilia-Romagna, Italy
between 2003 and 2009 among the adult population, aged
‡15 years; in the Italian health system, this is carried out by
the general practitioner.
Methods
Setting and study population
The study was performed in Emilia-Romagna, in northern
Italy, which has a population of over 4 million inhabitants,
with an average income in 2007 of € 32 802 per year [16],
higher than the European average of € 23 600. The average
yearly general healthcare expense in the region in 2008 was
€ 1829 per inhabitant [17]. Antibiotics accounted for 7.9% of
the total pharmaceutical costs and represent the fourth lead-
ing drug expense in the community setting in the region, the
ninth in the country [18,19]. The age of the population
remained stable throughout the study period (mean 45.4–
45.5 years).
Antibiotic consumption data
Antibiotics in Italy have to be prescribed by a physician, and
are not available as over-the-counter drugs. The majority of
antibiotics, i.e. >95%, are distributed from the National
Health Service free of charge for the patient, or with a mini-
mal charge (€ 1). Data on antibiotic prescriptions at the
patient level were obtained from the regional outpatient anti-
biotic database (Assistenza Farmaceutica Territoriale). Data
are recorded using the Anatomic Therapeutical Chemical
Classiﬁcation of the World Health Organization Collaborat-
ing Centre [20]. Demographic data were obtained from the
regional health service demographic database. A unique
patient identiﬁer is available in each database, permitting con-
nection of the different data sets.
The following parameters were evaluated: (i) prescrip-
tion: number of prescriptions of a certain drug, with a
limit of two packages of the same drug per prescription;
(ii) treatment: one or more prescriptions, repeated at
intervals of <10 days between one prescription and the
following one. Each treatment may contain one or more
prescriptions.
We considered only the population that is cared for by
the family doctors, i.e. ‡15 years old. Children up to
15 years of age are followed by paediatricians. Our analysis
took into account a total number of deﬁned daily doses
increasing from 20 507 825 in 2003 to 25 359 017 in 2009,
and representing 88.3–90.1% of antibiotics distributed in the
community setting.
Monthly analysis of antibiotic prescribing
To evaluate the effect of the inﬂuenza pandemics on antibi-
otic prescriptions, in particular the 2009 H1N1 pandemic,
we analysed the monthly antibiotic prescribing, expressed as
number of antibiotic treatments per 1000 persons, stratiﬁed
by age group. This analysis was performed for the last
3 years of the study period: 2007–2009.
Statistical analysis
The antibiotic consumption was analysed through different
parameters: (1) population exposed to antibiotics, expressed
as: (1a) the total number of inhabitants receiving at least one
and those receiving at least three antibiotic treatments; (1b)
the number of patients treated per 1000 inhabitants per day;
(2) total consumption: (2a) deﬁned daily dose per 1000 inhab-
itants per day (DID) [17]; (2b) prescriptions per 1000 inhabit-
ants per day; 2c) treatments per 1000 inhabitants per day.
These data were stratiﬁed for antibiotic class and age group
(15–19, 20–59, 60–79 and ‡80 years). The DID was calculated
for each of the 11 regional healthcare agencies. To evaluate
DID trends, the Poisson regression model was applied to
yearly consumption rates on the complete data set. No change
in antibiotic packaging was observed over the study period.
Analyses were performed using SAS version 9.1 (SAS Insti-
tute, http://www.sas.com/technologies/analytics/statistics). All
statistical tests were two-tailed; a p value of <0.05 was con-
sidered signiﬁcant.
Results
During the study period, the overall antibiotic consumption
in the adult population (‡15 years old) in Emilia-Romagna
increased from 15.4 DID in 2003 to 18.7 in 2009 (+21.4%;
p <0.0001) (see Fig. 1). Similarly, both the prescription and
treatment rates increased, respectively, from 1.92 to 2.19
prescriptions per 1000 inhabitants per day (+13.8%) and
from 1.68 to 1.91 (+13.2%). The number of patients treated
per 1000 inhabitants per day passed from 1.00 in 2003 to
1.09 in 2009 (+9%).
The highest antibiotic use was observed in the elderly
(‡80 years old) (see Fig. 1), and the highest increase in anti-
biotic use was seen among the population aged 20–59
(+24.7%). Men received overall about 14% less antibiotics
than women, although differences were observed among
age groups. Whereas young (age 15–19 years) and aged
(60–79 years) men and women had similar antibiotic use,
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men aged 20–59 years received around 30% less antibiotics
than similarly aged women because of the higher frequency
of uncomplicated urinary tract infections in fertile women.
Conversely, men aged ‡80 years were prescribed about 20%
more antibiotics than similarly aged women, because of a
higher frequency of respiratory tract infections and worse
general health (see Fig. 1). These differences between gen-
ders remained stable over the years.
The proportions of adults receiving at least one or three
or more antibiotic treatments were 36.4% and 3.5% in 2003
and increased steadily though 2009 to 39.7% (+9.1%) and
4.2% (+14.3%), respectively.
The analysis of the prescriptions per month of the year
for the period 2007–2009 showed a 41–90% increase in anti-
biotic use in the age group 15–19 years, for October and
November 2009, during the peak of the H1N1 pandemic,
compared with the same months during 2007 and 2008 (see
Fig. 2). A milder increase (37%) was observed in the age
group 20–59 years between November 2009 and 2008, only.
Antibiotic use returned to baseline levels in December 2009.
No other difference in antibiotic consumption was observed
in any other age group.
Penicillins were the most prescribed antibiotic class
throughout the study period and their use increased steadily
from 7.1 to 9.5 DID. This increase was mainly the result of
the rise in prescription of penicillin + beta-lactamase inhibi-
tor (PBLI) combinations, rising by 75%, from 3.6 to 6.3 DID.
A substantial increase was observed also for quinolones
(25%) and macrolides (19%), whereas cephalosporins
remained stable around 1.4 DID ()3%) (see Table 1).
FIG. 1. Antibiotic consumption expressed in deﬁned daily doses (DDD)/1000 inhabitants per day, in the adult population, divided by gender,
Emilia-Romagna 2003–2009.
FIG. 2. Proportion of people who were prescribed an antibiotic treatment, per month, divided by age group, Emilia-Romagna 2007–2009.
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Substantial differences were observed among the 11 health
agencies of the region: the antibiotic consumption varied
between 15.3 and 18.1 DID in 2003 and between 18.3 and
21.0 in 2008, with the relative increase ranging between
6.0% and 20.0%. Signiﬁcant differences in antibiotic prescrip-
tion habits and trends were observed among local health
agencies, particularly regarding the use of wide-spectrum
penicillins (WSP), i.e. amoxicillin and ampicillin, and PBLI. Use
of PBLI in 2009 varied in the different local agencies between
1.95 and 3.28 DID, with relative increases of 56–106%, com-
pared with 2003. Three different patterns of penicillin use
were identiﬁed: (i) wide prevalence of PBLI with a
PBLI : WSP ratio >2, in no agency during 2003 and in ﬁve
agencies in 2009; (ii) mild prevalence of PBLI use with
PBLI : WSP ratio between 1 and 2, in six agencies, but not
the same ones, both in 2003 and 2009; and ﬁnally, (iii) low
prevalence of WSP, with a PBLI : WSP <1, in ﬁve agencies in
2003 but none in 2009.
Quinolone use increased between 2003 and 2009, by
5–42%, from 2.04–2.81 to 2.42–3.52 DID. Similarly, macro-
lide use increased by 0.27–1.17 DID (8–48%). The use of
cephalosporins changed differently in the different areas,
ranging from a 29% decrease to a 22% increase.
Discussion
This analysis shows that antibiotic use in the adults residing
in Emilia-Romagna, Italy, is high, almost 20 DID, and that
between 2003 and 2009 there was a stable trend toward an
increase, at a rate of about 0.67 DID or 3%, per year. Fur-
thermore, over the last few years there has been a signiﬁ-
cant drift in the type of antibiotic prescribed, with an
increase in the use of PBLI, macrolides and quinolones, and a
reduction in the proportion, but not in the overall use, of
cephalosporins. The analysis, performed at the single health-
care agency level, showed that there are differences in antibi-
otic prescription habits even within the same region, with
variations of up to 2.7 DID, i.e. 15%; these are even more
evident when analysed at substance level. Striking dissimilari-
ties between neighbouring areas in the use of WSP com-
pared with PBLI were observed.
Despite this high antibiotic consumption rate Emilia-Ro-
magna is performing better than the national average of
25.1 DID in 2008 [18]. Wide variations are observed
within the country, ranging from 16.1 DID in the province
of Bolzano to 34.9 DID in Sicily and 39.9 DID in Campa-
nia, with national trends towards an increase. This con-
stant trend toward an increase in antibiotic use is
worrying and indicates that a public health intervention to
control antibiotic use is imperative. This trend has been
observed despite the lack of evident factors, such as an
increase in morbidity or mortality among the population,
or signiﬁcant bacterial outbreaks and epidemics, i.e. involv-
ing >100 inhabitants, being reported by the regional alert
system [21], with the exception of the H1N1 pandemic.
Furthermore, because of the limited number of new antibi-
otics registered for community-acquired infections in this
time, no strong marketing pressure was observed from the
pharmaceutical industry. On the other hand, some com-
monly prescribed antibiotics, such as co-amoxiclavulate or
ceftriaxone, became generics. The loss of patent of these
and other antibiotics may represent a confounding factor
because the national and regional antibiotic expenditure is
decreasing, despite an increase in antibiotic use, making
public health interventions on antibiotics less impellent to
the administrators [18].
Most importantly a constant trend toward an increase in
antibiotic resistance particularly regarding Enterobacteriaceae
has been observed within our region. Among Escherichia coli
isolates the proportion of third-generation cephalosporin-
resistance in blood isolates rose from 4.7 to 22.9%
between 2003 and 2009. Similar antibiotic resistance trends
have been observed among other Enterobacteriaceae, partic-
ularly Klebsiella pneumoniae. In contrast, both methicillin-
resistance rates among Staphylococcus aureus isolates and
TABLE 1. Antibiotic consumption expressed as deﬁned daily doses (DDD)/1000 person days, Emilia-Romagna 2003–2009
ATC code Antibiotic class
DDD/1000 inhabitant-days
2003 2004 2005 2006 2007 2008 2009
J01CR Penicillin + beta-lactamase inhibitor 3.6 4.0 4.3 4.5 5.3 5.9 6.3
J01CA Penicillins with extended spectrum 3.5 3.6 3.7 3.5 3.5 3.5 3.2
J01FA Macrolides 3.1 3.2 3.3 3.2 3.4 3.6 3.7
J01M Quinolones 2.6 2.7 3.0 3.1 3.2 3.2 3.1
J01DB, J01DC, J01DD, J01DE Cephalosporins 1.4 1.4 1.5 1.4 1.4 1.4 1.4
J01EE01 Trimethoprim + sulfamethoxazole 0.4 0.4 0.4 0.4 0.3 0.3 0.3
J01XX01 Fosfomycin 0.3 0.3 0.3 0.3 0.3 0.3 0.3
Other 0.3 0.3 0.3 0.3 0.3 0.4 0.4
ATC, Anatomic Therapeutical Chemical Classiﬁcation of the World Health Organization Collaborating Centre.
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ceftazidime-resistance among Pseudomonas aeruginosa strains
remained stable around 40% and 30%, respectively [11].
The rising trend observed in our region is similar to what
has been reported in other countries where no intervention
by the public health sector aimed at controlling antibiotic use
has been performed, such as Ireland or Israel [22]. Although
a possible explanation of this trend in antibiotic over-pre-
scription may be related to cultural and communication
problems, both at the doctor and the population levels, as
already identiﬁed in the paediatric population by our group
[23], it is well known that different strategies to control anti-
biotic consumption, including pamphlets and posters, print
media, billboards, radio, television, websites, letters, guide-
lines, seminars, academic detailing, targeting both the public
and the physicians, can be successful [24]. The French antibi-
otic campaign, launched in 2001 and based on the slogan Les
antibiotiques, c’est pas automatique (Antibiotic, it is not auto-
matic), is a clear example of how a country with a high anti-
biotic use can signiﬁcantly reduce it through a nationwide
intervention [25]. As the French experience shows, such an
intervention is expensive but may be able to generate large
money savings: the total amount of money spent on systemic
antimicrobials fell from € 1026 million in 2001 to € 669 mil-
lion in 2008 ()35%), with a total saving from 2002 through
2008, based upon 2001 expenditures, of € 1.4 billion [26].
Cost-effectiveness of antibiotic-use campaigns has been
shown to be good, even investing relatively high amounts of
money. The French campaign cost some € 500 million for
6 years, i.e. about € 0.8 per inhabitant per year [27]: the net
savings have then been slightly less than € 1 billion. Other
campaigns, such as the Belgian one, although still having
interesting results, had much lower costs, i.e. € 380 000, or
€ 0.04 per patient per year [28]. The French per-capita
investment would be equivalent, in Italy, to 10–30% of the
cost of one single box of a common antibiotic. These
amounts are much lower than those dedicated to promoting
antibiotic use by the pharmaceutical companies, estimated to
be about $ 5 per patient per year [29]. Finally, and probably
most importantly, the reduction in antibiotic use has been
associated with a reduction in antibiotic resistance [30]. We
did not observe any signiﬁcant change in antibiotic prescrip-
tions after the introduction of European Antibiotic Aware-
ness Day in 2008 nor in 2009, compared with 2007,
particularly during the winter season, possibly because of the
limited time available for the trend analysis and the H1N1
pandemic.
Our analysis has some limitations, the ﬁrst and most
important being that, based upon International Medical Statis-
tics, the reported data represent a 20% underestimation of
the real antibiotic consumption, as previously reported [31].
Furthermore, over the last 3 years, an increasing proportion
of antibiotics, in 2009 around 4%, have been distributed
directly on discharge from the hospital, representing a sec-
ond cause of underreporting.
In conclusion, antibiotic use in Emilia-Romagna has steadily
increased over the last 7 years. One intervention was imple-
mented in 2010, a regional project on hospital antimicrobial
stewardship. Furthermore, a campaign on wise antimicrobial
use in the community setting in two provinces is being
devised, and will be launched in autumn 2011. While awaiting
the results of these interventions, new programmes are nec-
essary, such as regional or national guidelines for common
community-acquired infections. We feel that each country or
region with a high level of antibiotic consumption should
implement a local campaign on antibiotic use, possibly proﬁt-
ing from the European Centres for Disease Control cam-
paign and material, which are freely available on the internet.
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